Evogene Ltd.·3

Mar 18, 9:23 AM ET

RECANATI LEON 3

3 · Evogene Ltd. · Filed Mar 18, 2026

Insider Transaction Report

Form 3
Period: 2026-03-18
Holdings
  • Ordinary shares

    83,886
  • Stock Option (right to buy ordinary shares)

    Exercise: $72.46From: 2020-06-11Exp: 2026-05-18Ordinary shares (250 underlying)
  • Stock Option (right to buy ordinary shares)

    Exercise: $54.32From: 2021-06-11Exp: 2027-05-16Ordinary shares (250 underlying)
  • Stock Option (right to buy ordinary shares)

    Exercise: $32.05From: 2022-06-11Exp: 2028-06-25Ordinary shares (250 underlying)
  • Stock Option (right to buy ordinary shares)

    Exercise: $17.68From: 2023-06-11Exp: 2029-07-30Ordinary shares (250 underlying)
  • Stock Option (right to buy ordinary shares)

    Exercise: $12.03From: 2024-06-11Exp: 2030-11-17Ordinary shares (250 underlying)
  • Stock Option (right to buy ordinary shares)

    Exercise: $39.32From: 2025-06-11Exp: 2031-06-11Ordinary shares (250 underlying)
  • Stock Option (right to buy ordinary shares)

    Exercise: $28.62From: 2022-08-10Exp: 2031-09-01Ordinary shares (1,800 underlying)
  • Stock Option (right to buy ordinary shares)

    Exercise: $10.50From: 2023-09-15Exp: 2032-09-15Ordinary shares (1,800 underlying)
  • Stock Option (right to buy ordinary shares)

    Exercise: $6.03From: 2024-05-11Exp: 2033-05-11Ordinary shares (1,800 underlying)
  • Stock Option (right to buy ordinary shares)

    Exercise: $7.16From: 2025-06-13Exp: 2034-06-13Ordinary shares (1,800 underlying)
  • Stock Option (right to buy ordinary shares)

    [F1]
    Exercise: $1.29Exp: 2035-08-18Ordinary shares (2,500 underlying)
Footnotes (1)
  • [F1]The options reported in this row vest equally on a quarterly basis (25% per quarter) such that they will be fully vested on the one-year anniversary of the August 18, 2025 grant date.
Signature
/s/ Nitsan Deutsch, attorney-in-fact|2026-03-18

Documents

2 files
  • 3
    ownership.xmlPrimary
  • EX-24.1

    EXHIBIT 24.1